Company news
Hua Medicine Ltd. (HKEX:2552) news
Hua Medicine Ltd. news releases on 6ix. Latest, Aug 22, 2026: Hua Medicine Announces 2026 Interim Results
Press releases & updates
Hua Medicine Announces 2026 Interim Results
August 22, 2026
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
March 3, 2026
Hua Medicine Announces 2025 Interim Results
August 28, 2025
Hua Medicine Announces 2024 Annual Results
March 28, 2025
Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award
November 4, 2024
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award'
October 24, 2024
Hua Medicine Announces 2024 Interim Results
August 30, 2024
Hua Medicine Announces 2023 Interim Results
August 25, 2023
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China
October 9, 2022
Hua Medicine Announces 2021 Annual Results
March 16, 2022
Hua Medicine : Announces 2020 Interim Results
August 19, 2021
Hua Medicine : Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally
April 23, 2021
Hua Medicine Shanghai : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR DORZAGLIATIN ACCEPTED IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
April 23, 2021
Hua Medicine Shanghai : Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission
March 19, 2021
Hua Medicine : Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial
December 17, 2020